Skip to main content
  • RUCONEST® business performed strongly in 2Q 2023; continue to anticipate low single digit annual revenue growth

  • Strong start to U.S. Joenja® launch during 2Q 2023; 43 patients on paid therapy and US$3.8 million revenue

  • 1H 2023 revenues increased 1% to US$97.4 million, compared to 1H 2022

  • 2Q 2023 revenues increased 9% to US$54.9 million, compared to 2Q 2022, driven by strong RUCONEST® revenues and the U.S. commercial launch of Joenja®

  • RUCONEST® revenues increased 20% in 2Q 2023 to US$51.1 million, compared to 1Q 2023, but decreased 3% in 1H 2023 compared to 1H 2022

  • Overall cash and cash equivalents, including restricted cash, of US$194.1 million at the end of 2Q 2023, compared to US$186.2 million at end of 1Q 2023

  • Strong progress in efforts to make leniolisib available to APDS patients in key markets globally - CHMP opinion expected 4Q 2023, regulatory submissions filed in Canada, Australia, and Israel, and named patient program launched

Pharming held a presentation for analysts and investors at 13:30 CEST/07:30 EDT on August 3, 2023 (rewatch webcast). Presentation slides and transcript can be found below. 

Chief Executive Officer, Sijmen de Vries, commented:

"The second quarter of 2023 was strong for Pharming and RUCONEST® recovered significantly in the second quarter increasing 20% over the first quarter of 2023... The Joenja® (leniolisib) U.S. launch got off to a strong start with the first reimbursed shipments to patients taking place in April; within two weeks of FDA approval." 


Cookies: This website uses cookies Check the cookies page for more information Accept Decline